A technical information page focused on composition, practical use, rationale and selected scientific literature concerning ingredients and bioactive compounds relevant to the product. The purpose is educational, not promotional, and the content is intended to support a medical-scientific discussion [1][2][3][4][5].
GastroNYX Plus is a food supplement based on Aloysia triphylla and an Ajuga reptans cell-culture extract, both used for digestive function, with Althaea officinalis supporting a soothing and emollient effect on the digestive tract.
It may be considered as an adjunct nutritional option, within an appropriate diet and after clinical assessment, in subjects with:
This page does not present GastroNYX Plus as a pharmacological alternative to PPIs or other treatments. The product is not positioned as an antacid and is not intended to diagnose, treat or cure disease. Use should always be framed within professional clinical judgement [1][6].
1 tablet per day, to be swallowed or, in case of reflux, to be dissolved in the mouth. In this case, after taking it, avoid food or drinks for approximately 15 minutes in order to promote a topical action and not wash out the active molecules of GastroNYX. Take preferably in the morning upon getting up or in the evening before going to bed: in case of pharmacological therapy with PPIs or alginates, take GastroNYX apart (for example, PPIs in the morning and GastroNYX in the evening). There is no pharmacological interference but the indicated drugs create a barrier that makes it more difficult for the active molecules of GastroNYX to act on the mucosa. It can be taken both on a full and empty stomach [1].
| Ingredient | Amount / 1 tablet | Standardisation | Functional note |
|---|---|---|---|
| Aloysia triphylla dry extract | 76 mg | Acteosides 19 mg | Digestive function[2] |
| Althaea officinalis root extract | 60 mg | Mucilage 12 mg | Soothing and emollient effect on the digestive system |
| Ajuga reptans | 30 mg | Teupolioside 3 mg | Preclinical interest in intestinal inflammatory pathways |
| Pharmaceutical form | 30 orodispersible tablets, 500 mg each | ||
The product rationale rests on three complementary pillars:
In practical terms, this medical page frames the product as nutritional support focused on mucosa, digestive function and a phytonutritional rationale, rather than as a simple acid-neutralising approach.
The evidence summarised below includes preclinical studies and technical/regulatory documents on individual compounds or extracts relevant to the product profile. References are reported transparently and should not be read as definitive clinical proof for the finished product [1][2][3][4][5].
The review by Alipieva et al. describes acteoside as a phenylethanoid glycoside with antioxidant and anti-inflammatory activities. More recent literature, also reflected in the ISF technical sheet, discusses interactions with NF-κB, TNF-α, IL-1β, COX-2, iNOS and pathways such as MAPK e PI3K/AKT [1][3].
The EMA assessment report on Aloysia triphylla describes a history of traditional use in the digestive area, including dyspepsia, gastrointestinal complaints, stomach ache and indigestion [2].
In an animal model of 5-FU-induced mucositis, acteoside attenuated increases in inflammatory and tissue-damage biomarkers, alongside histological improvement across the gastrointestinal tract, from the oesophagus to the colon [5].
López-Rodríguez et al. evaluated fractions and isolated compounds in an experimental stress-induced gastric lesion model. In that setting, acteoside markedly reduced ulcerated area, with inhibition close to 99.8% compared with the vehicle group [4].
In the 2025 Medical Oncology study, 5-fluorouracil induced widespread biochemical and histological alterations in the gastrointestinal tract. acteoside attenuated these changes, with a trend towards better outcomes at the higher dose [5].
| Parameter | Effect of 5-FU | Reported effect of acteoside |
|---|---|---|
| TNF-α, IL-1β | Increase | Attenuation of the increase [5] |
| MMP-1, MMP-2, MMP-8 | Increase | Reduction / attenuation [5] |
| TIMP-1 | Decrease | Trend towards recovery [5] |
| ALP, AST, LDH | Increase | Attenuation [5] |
| Oesophagus-to-colon histology | Degeneration and desquamation | Improved organisation / re-epithelialisation [5] |
The EMA/HMPC report on Aloysia triphylla provides regulatory and historical context for interpreting the formulation. The document refers to traditional uses associated with:
Value of the data: it supports the digestive-use coherence of Aloysia within the formula, while remaining distinct from specific clinical proof in reflux disease.
GastroNYX is indicated as an adjuvant in case of:
GastroNYX is indicated as an adjuvant in case of:
Use caution in transplant recipients undergoing immunosuppressive therapy, as the active ingredients in GastroNYX have immune-modulating properties.
Food supplements should not be used as a substitute for a varied, balanced diet and a healthy lifestyle. Keep out of reach of children under 3 years of age. Excessive consumption may have laxative effects. Store in a cool, dry place [1].
GastroNYX Plus is available through pharmacies and directly at the company’s operational premises in Trento: Via Alla Veduta 84, 38121 Trento, Italy. Local availability and access can be checked through the company.
